”Based on the observations to date, the Company plans to move forward with scale-up activities to support further development and clinical studies that would support regulatory submissions. If one of the imaging methods is shown to be effective in pivotal studies, the MagSense® HER2 test would be commercialized as a non-invasive alternative reducing the need for biopsies for nodal staging".
Now would they move forward if the NP's didn't quantitate correctly? LMAO and these DownRamping attempts!
Ann: First-in-human Study Progress Update, page-54
-
- There are more pages in this discussion • 142 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
